

Anti-PDCD1/PD-1/CD279 Antibody (Zimberelimab)

Introduction

Zimberelimab (GLS-010) is a whole-body IgG4 anti-PD-1 Monoclonal antibodies, human PD-1 of EC₅₀ is 210 pM. Zimberelimab can effectively block the PD-L1 and PD-L2 on cell surface PD-1. The combination of IC₅₀ The values are 580 pM and 670 pM, respectively. Zimberelimab has antitumor activity and is used in a variety of cancer studies, including cervical cancer, non-small cell lung cancer, and classical Hodgkin lymphoma.

Product parameters

Alternative Names	WBP3055, GLS-010, AB122
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	2259860-24-5
Molecular Weight	146.54 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

